Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As I understand it the average drug development time to approval is about 10 years.
I do agree with you that some of the data should have been released by now. As for the discussions about AA and BTD weren't those here on the board? I don't recall the company discussing those things.
We all wish things had progressed faster.
It is my opinion that the MAA has been filed based on the date of the centralized procedure PR and conversations with IR. If I am wrong on that it should be filed soon.
You are not the only one that feels that this has taken longer than expected. I join you in that. Alas, hindsight is not helpful in this case.
When I bought my shares in 2015, I did NOT think that 9 years later we’d still not have filed an NDA, not released full PDD & ALZ data, revealed the undisclosed CNS condition, etc. There was also discussion of AA or BTD which of course never materialized as well.
I would not have tied up my money for the last 9 years (opportunity cost) if I had known how slowly this would proceed. I’m pretty sure that I’m far from the only one who feels this way.
Let's start with your 9 year horizon. Does that assume that Anavex should have had a drug on the market 9 years ago or submitted to the FDA 9 years ago? Is that the baseline you are using for your 9 years starting point?
I don't win every argument or even most of them. I do bring facts and reasonable assumptions to the discussion and I try to back up my opinions with data to support them.
Others not so much.
So yeah, I think your 9 year premise is a straw man. And I'm not using ad hominem attacks. I just disagree with your statement.
Pazzo - do you know how the 630PM presentation was received? Was it important?
While I do weigh in on what Investor writes, I am an individual investor who believes in listening to all sides of an argument.
I came on board as a shareholder in July 2015, purchasing the majority of my pre-reverse split shares between 75 and 90 cents.
I abhor unfounded hype and hysteria, and much prefer level-headed debate on both the long and short side.
I hope we’ve got the goods here, but hope only goes so far.
SAVA has shown that a strong CEO and clear communication do matter. Anavex has a blabbering CEO, making it necessary to reread transcripts multiple times to understand them. Hopefully, he deliver at AAIC; otherwise, be prepared for a potential rug pull Monday.
Short term gain? Is 9 years a short term horizon in your estimation?
Your type is never wrong—you must have to win every argument that you have with others.
Your math is speculative. It assumes immaculate trading is the norm.
Sure, If I had sold at $24.582, the close of that intraday high you are so proud of, I would have more money in my trading account. Of course I would have had to not buy back in for a month or more to realize any significant position increase.
Your math isn't wrong, your premise is wrong.
I and many others are not in Anavex for the short term gain, I'm in it for the long term gain.
So, let's revisit this discussion in the future when it counts.
No, it doesn't matter.
That is history.
What matters it what is coming. And, I like what I see coming.
The more guys like you and Investor post, the more I buy. We all know why you are here. Sad way to spend your life.
In since 39 cents pre reverse split. Thanks for your genuine concern for all of us.
Did you notice that last Friday AVXL closed at $5.48?
Seems like a pretty good week to me. The sort of thing that suggests positive expectations.
If there was to be something new from Dr. Sabbagh, a release would come before he speaks on Sunday.
Put another way, if you lose $25, but gain $3, are you not still down $22?
Think about it and let me know if my math is wrong.
Really?
Did you happen to notice how much AVXL is up in a week?
Yes, but I also happen to notice how much it’s down from it’s all-time high. Or, does that not matter?
It was adown day. Did you happen to notice how much AVXL is up for the week?
Or, is that sort of context not in your interest?
"Well, that was a schitty day" It sure makes on wonder WHO bought 120,000 shares MOC Market On Close for $6.74 pps????
John k9uwa
A lot wishful thinking being posted despite the lack of any announcement from the company - as if some secret wonderfulness is in the works.
The company has not announced its participation, so unlikely to be presenting anything new unfortunately.
Down just a bit after a nice run. Some are likely relieved.
Considering today's market and all the upcoming speeches at the press conference it's a very disappointing day I would say the street is not expecting much
Perhaps Missling will choose to announce leasing space @ The Spiral.
Spending all that WGT earnings a bit early?
The only one that really matters is the one does not start until 6:30pm ET.
Obviously the question of whether $AVXL will ever be a $8 stock again remains a good one.
Well, that was a schitty day.
I haven’t seen a roulette table for a good while, but obviously meant red and black.
" should we expect a PR"---not at all expecting a PR on a Sunday---wish I was wrong !!!!
Another anticlimactic trading day for Anavex leading into this weekend’s AAIC conference. Once again, so much anticipation leading into this weekend, only to have it flatline with today’s SP inaction.
I was hopeful it might be different this time, but this company has a way of falling short on expectations and delivering disappointment.
Well, that was a schitty day.
Especially interesting given SAVA's performance today...
Looks like we'll finish right at the low of the day.
Almost too late buying AVXL stock today
This coming Sunday 28 July 2024 Dr. Marwan N Sabbagh, MD will be make an oral presentation at the 2024 AAIC Meeting concerning the results from the Phase 2b/3 Alzheimer's trial using blarcamesine.
That means that Friday 26 July 2024 will be the last time for the shorts to cover before the AAIC Meeting!!!
Good luck and GOD bless,
Oh well...maybe next week.
What is the title? Sounds like it must not be too impressive if you are too scared to show it every time you have been asked...
Yeah, I thought the momentum would carry a lot higher especially today !
The RSI gave the signal by not confirming the price push up, rather it was unable to register a new high along with the stock...
Same as last Friday, they ran it up to sell some calls and then caused them to expire OTM. It’s the 7’s this week.
Quote: "EMA already have it [brain volume] as a surrogate biomarker."
Where did you get that information? (And please provide a link to the information)
Thanks
Feedback yet from AVXL presentations by Anavex..Fragile X, for example.???TIA...
26 July 2024 three presentations concerning Anavex conference
27 July 2024 one presentation regarding Anavex at the Fragile X conference
28 July 2024 one presentation concerning Anavex at the Alzheimer’s disease conference
29 July 2024 one presentation concerning Anavex at the Alzheimer’s disease conference
So if it’s new data on Sunday the 28th, should we expect a PR on that day?
Not sure if I’ve ever seen a PR on a Sunday. Anyone?
re: Their answer at the EMA will be Blarcamesine
Does the EMA have a Phase 4 type conditional approval/P4 trial system?
I was in the pool!
"... then it would be a great time to play green ... he nearly always left the casino a bit poorer than he went it ..."
Of course, he went home poorer ... he should have played black as there are many more black slots than green! 😉
Not as expected by me so far............😞
EF Hutton Initiates Coverage of Anavex Life Sciences (AVXL) with Buy Recommendation
Posted by RedShoulder a couple of days ago. Nice find RS..
Analyst Price Forecast Suggests 374.62% Upside - Very undervalued here at $6.80
https://www.nasdaq.com/articles/ef-hutton-initiates-coverage-anavex-life-sciences-avxl-buy-recommendation
…plus better sleep and lowering hypertension.
https://www.anavex.com/post/anavex-life-sciences-announces-issuance-of-new-u-s-patent-anavex-2-73-blarcamesine
https://www.verywellhealth.com/systolic-and-diastolic-blood-pressure-1746075
🫀🧠🫶
Anavex has been saying for a while that its FragileX trial will be pivotal, which I take to mean P3.
Your conditionals are as good as mine.
But for safe drugs which show signal in unmet indications is a lot higher than 50% in EMA's eyes.
Interesting that their graphic shows Fragile X has entered in the Phase 3 portion.
Let’s set aside AD as a prerequisite for getting 2-73.
Based on its safety profile I would be interested in taking a pill that limits brain shrinkage for any reason.
Look for a SHORT SQUEEZE running into the close of treading today!!!
Good luck and GOD bless,
🏁🏁🏁 https://www.anavex.com/sigmaceptor-explained 🏁🏁🏁
Going to be a lot of receptive and responsive patients positively affected after the EMA approval. 🧠💡
Followers
|
1074
|
Posters
|
|
Posts (Today)
|
156
|
Posts (Total)
|
465065
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |